For instance, approximately half of AYA breast cancer patients less than 30 years of age carry a germline mutation in BRCA or TP53, AYA breast cancer patients have a nine-fold higher local recurrence risk after breast conserving therapy compared to women over the age of 60, and 39% of AYA women with early-stage breast cancer are more likely to die compared to older women [40,41,42]. Here, TP53 is linked to breast carcinoma.